Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+2.96%
$6.36
100% positive prob.
5-Day Prediction
+6.11%
$6.56
100% positive prob.
20-Day Prediction
+1.38%
$6.27
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +2.96% | +6.11% | +1.38% | 100.0% | Pending |
| Q2 2026 | SELL | -4.78% | -11.04% | -3.43% | 100.0% | +9.31% |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
+2.96%
$6.36
Act: +4.15%
5D
+6.11%
$6.56
20D
+1.38%
$6.27
2 atyr-ex99_1.htm
Exhibit 99.1
Contact:
Ashlee Dunston
Investor Relations and Public Affairs
adunston@atyrpharma.com
aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated.
Company to prioritize strategic partnerships to advance Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Ended the third quarter 2026 with $50.3 million in cash, cash equivalents, restricted cash and investments; cash runway into late 2028 based on current operational plans.
SAN DIEGO – November 5, 2026 – aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2026 results and provided a corporate update.
“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”
Third Quarter 2026 and Subsequent Period Highlights
• Reached alignment with the FDA on the protocol for a global Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The Company recently initiated study-related activities for the trial and is prioritizing strategic partnerships and/or licensing arrangements in order to advance the Phase 3 study beyond the completion of the initial study-related activities.
• Completed enrollment in the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with limited or diffuse systemic sclerosis (SSc)-related ILD (SSc-ILD). Full study results are expected in the second quarter of 2027. These will include data for multiple study endpoints, including the
modified Rodnan Skin Score, skin histopathology, gene expression profiling, immune biomarkers, forced vital capacity, and an exposure response analysis.
• Published the results of the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine. The peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care. The publication is available on the Company’s website.
• Published a manuscript demonstrating the mechanism of action and anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 is a fusion protein that interacts with latent transforming growth factor beta binding protein 1 (LTBP-1) through a unique way that presents a differentiated approach to targeting fibrosis. The publication is available on the Company’s website.
• Announced a research collaboration for pediatric osteosarcoma with Montefiore Einstein involving preclinical studies of ATYR2810, the Company’s monoclonal antibody that targets the neuropilin-2 (NRP2) receptor. The collaboration is to further the development and testing of ATYR2810 in an aggressive cancer where NRP2 is implicated.
Third Quarter 2026 Financial Highlights and Cash Position
• Cash & Investment Position: Cash, cash equivalents, restricted cash and available-for-sale investments as of September 30, 2026, were $50.3 million. Based on its current cash and operating expense forecast and plans, the Company anticipates that this cash position will be sufficient to fund the Company’s current operations into late 2028.
• R&D Expenses: Research and development expenses were $10.4 million for the third quarter 2026, which consisted primarily of costs for the Phase 2 EFZO-CONNECT™ study and research and development costs for the Company’s preclinical product candidates.
• G&A Expenses: General and administrative expenses were $8.3 million for the third quarter 2026.
About Efzofitimod
Efzofitimod is a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. Efzofitimod is currently being investigated in the Phase 2 E
Aug 7, 2026 · 100% conf.
1D
-4.78%
$0.49
Act: +3.42%
5D
-11.04%
$0.45
Act: +9.31%
20D
-3.43%
$0.49
2 atyr-ex99_1.htm
Exhibit 99.1
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.
Workforce reduction of approximately 60% and program prioritization conserves capital and aligns resources on efzofitimod program in ILD.
Enrollment completed in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD; topline results expected in the first quarter of 2027.
Ended the second quarter 2026 with $58.9 million in cash, cash equivalents, restricted cash and investments; cash runway into late 2028 based on current operations.
SAN DIEGO – August 7, 2026 – aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease (ILD), including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD).
The program prioritization aims to focus the Company’s resources on advancing its lead asset, efzofitimod, and targeted pipeline development to conserve capital in anticipation of receiving comments from the U.S. Food and Drug Administration (FDA) on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, a major form of ILD. The Company submitted the protocol in June 2026 and is expecting feedback from the FDA by the end of August 2026.
“We are proactively taking decisive, necessary action to focus our resources on our lead therapeutic candidate, efzofitimod, as we await feedback from the FDA on the protocol we submitted for our planned Phase 3 study in pulmonary sarcoidosis patients with restrictive lung disease. This approach positions aTyr to advance this planned Phase 3 study efficiently and continue completing the Phase 2 EFZO-CONNECT™ study in SSc-ILD,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We remain confident in the potential of efzofitimod to become a meaningful therapy for patients with these forms of ILD, and these changes are essential to our ability to achieve that goal. We are deeply grateful to our dedicated team members for their
outstanding contributions, commitment, and perseverance, including those who have helped advance tRNA synthetase biology over the years.”
Program Prioritization and Corporate Restructuring
• Workforce reduction of approximately 60% will align organizational resources to support the efzofitimod program in ILD in anticipation of comments from the FDA on a protocol submitted for a planned Phase 3 study in pulmonary sarcoidosis and to complete the Phase 2 EFZO-CONNECT™ study in SSc-ILD.
• Jill Broadfoot, aTyr’s Chief Financial Officer (CFO), will step down as of September 30, 2026, and transition to serve as a consultant to the Company. Brandon Yaras, aTyr’s Vice President of Finance, will be appointed as CFO as of October 1, 2026.
• Nancy Denyes, aTyr’s General Counsel, will step down as of September 30, 2026, and transition to serve as a consultant to the Company.
• The Company expects that this restructuring and additional cost saving measures will reduce annualized operating expenses by approximately $13 million, beginning in the fourth quarter of 2026.
Second Quarter 2026 and Subsequent Period Highlights
• Protocol submitted to FDA in June 2026 for planned Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The Company is expecting feedback from the FDA by the end of August 2026. The Phase 3 trial is expected to be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study will consist of two parallel cohorts randomized equally to either 5.0 mg/kg efzofitimod or placebo dosed intravenously once every 3 weeks for a total of 17 doses. The study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are receiving a stable dose of ≤ 5.0 mg daily oral corticosteroid and/or a background immunosuppressant. All background treatment will remain stable throughout the duration of the study. The primary endpoint of the study will be change from baseline in forced vital capacity (FVC) at week 48 and the key secondary endpoint will be change from baseline in the King’s Sarcoidosis Questionnaire-Lung score at week 48.
• Enrollment completed in the Phase 2 EFZO-CONNECT™ study to evaluate th
May 15, 2026
2 atyr-ex99_1.htm
Exhibit 99.1
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA.
Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.
On track to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026.
Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments.
SAN DIEGO – May 15, 2026 – aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2026 results and provided a corporate update.
“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), following our recent Type C meeting with the U.S. Food and Drug Administration (FDA),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Based on feedback from the FDA, we plan to file an investigational new drug (IND) application next month for a new Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing forced vital capacity (FVC) as the primary endpoint of the study and the King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint. We look forward to the continued advancement of efzofitimod in this form of ILD where there remains a high unmet medical need.”
First Quarter 2026 and Subsequent Period Highlights
• Announced plans to continue the development of efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. The Company plans to file an IND in June 2026 for a new Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as the primary endpoint of the study and the
KSQ-Lung score as the key secondary endpoint. The Phase 3 trial is expected to be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study will consist of two parallel cohorts randomized equally to either 5.0 mg/kg efzofitimod or placebo dosed intravenously once every 3 weeks for a total of 17 doses. The study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are receiving a stable dose of ≤ 5.0 mg daily oral corticosteroid and/or a background immunosuppressant. All background treatment will remain stable throughout the duration of the study. The primary endpoint of the study will be change from baseline in FVC at week 48 and the key secondary endpoint will be change from baseline in the KSQ-Lung score at week 48.
• On track to complete enrollment in the Phase 2 EFZO-CONNECT™ study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with limited or diffuse systemic sclerosis (SSc, or scleroderma)-related ILD (SSc-ILD) in the first half of 2026. This proof-of-concept study is a randomized, double-blind, placebo-controlled, 28-week study consisting of three parallel cohorts randomized 2:2:1 to either 270 mg or 450 mg of efzofitimod or placebo administered intravenously monthly for a total of six doses. The study intends to enroll up to 25 patients at multiple centers in the United States. Promising interim data from the study were reported in the second quarter of 2025.
• Poster related to the Company's investigational new drug candidate, ATYR0101, accepted for presentation at the Extracellular Matrix Pharmacology Congress, which is scheduled to take place June 14 – 17, 2026 in Copenhagen, Denmark. The poster, which is titled, “Natural Asp-tRNA Synthetase Fragment Interacts with LTBP-1 on the ECM Promoting Myofibroblast Apoptosis and Reducing Fibrosis,” presents research indicating that AYTR0101 selectively induces myofibroblast apoptosis via modulation of focal adhesion kinase (FAK) signaling through a novel binding interaction with latent-transforming growth factor beta binding protein 1 (LTBP-1) and results in a significant reduction of fibrosis in lung and kidney models. The poster will be available on the Company’s website once presented.
First Quarter 2026 Financial Highlights and Cash Position
• Cash & I
This page provides aTyr Pharma Inc. (ATYR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ATYR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.